Generic Name and Formulations:
Butalbital 50mg, acetaminophen 325mg; tabs.
Various generic manufacturers
- Dexcom G6 Integrated Continuous Glucose Monitoring System Gets FDA Approval
- New Continuous Glucose Monitoring System Now Available for Medicare Patients
- Acetaminophen Interference With Blood Glucose Readings: What Clinicians Need to Know
Indications for Butalbital/Acetaminophen:
Tension (or muscle contraction) headache.
1–2 tabs every 4 hours; max 6 tabs daily.
Extended use: not recommended. Severe renal or hepatic impairment. Acute abdominal conditions. Elderly. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended.
Barbiturate + analgesic.
Potentiated by alcohol, other CNS depressants, MAOIs. May cause false (+) urine test for 5-hydroxyindoleacetic acid.
Drowsiness, dizziness, paradoxical excitement, rash; overdosage: respiratory depression, hepatotoxicity.
Formerly known under the brand name Phrenilin.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Fatigue Management Contributes to Effective Endometriosis Care
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Trulicity Labeling Updated to Include Data on T2D Patients With CKD
- New Data Support Long-Term Cardiovascular Safety of Linagliptin in T2D
- Peer-Led Education Helps Physicians Save Time With EHRs
- As Immigration Policies Tighten, Physician Shortage Concerns Grow